Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine in elderly patients with advanced pancreatic cancer.
Hentic O, Dreyer C, Rebours V, Zappa M, Lévy P, Raymond E, Ruszniewski P, Hammel P. Hentic O, et al. Among authors: dreyer c. World J Gastroenterol. 2011 Aug 14;17(30):3497-502. doi: 10.3748/wjg.v17.i30.3497. World J Gastroenterol. 2011. PMID: 21941416 Free PMC article.
Sunitinib in pancreatic neuroendocrine tumors.
Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S. Raymond E, et al. Among authors: dreyer c. Target Oncol. 2012 Jun;7(2):117-25. doi: 10.1007/s11523-012-0220-2. Epub 2012 Jun 2. Target Oncol. 2012. PMID: 22661319 Review.
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E. Faivre S, et al. Among authors: dreyer c. Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531821 Clinical Trial.
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E. Pellat A, et al. Among authors: dreyer c. Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8. Neuroendocrinology. 2018. PMID: 29518779 Clinical Trial.
[PI3K-AKT-mTOR pathway and cancer].
Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E. Coutte L, et al. Among authors: dreyer c. Bull Cancer. 2012 Feb 1;99(2):173-80. doi: 10.1684/bdc.2011.1384. Bull Cancer. 2012. PMID: 21742593 Free article. Review. French.
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Ronot M, et al. Among authors: dreyer c. Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20. Oncologist. 2014. PMID: 24652387 Free PMC article.
256 results